Lineage Cell Therapeutics
LCTX
$1.05
Share price
-7.08%
Change (1 day)
-19.85%
Change (1 year)
Categories
P/S ratio for Lineage Cell Therapeutics (LCTX)
P/S ratio as of May 2024 (TTM): 23.8
According to Lineage Cell Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 23.817. At the end of 2023 the company had a P/S ratio of 21.3.
P/S ratio history for Lineage Cell Therapeutics from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 21.3 | 57.65% |
| 2022 | 13.5 | -87.24% |
| 2021 | 106 | -68.96% |
| 2020 | 342 | 278.58% |
| 2019 | 90.2 | 10.04% |
| 2018 | 82.0 | -46.14% |
| 2017 | 152 | -8.1% |
| 2016 | 166 | 13.12% |
| 2015 | 146 | -2.39% |
| 2014 | 150 | 110.2% |
| 2013 | 71.4 | -91.97% |
| 2012 | 888 | 1238.34% |
| 2011 | 66.4 | -34.46% |
| 2010 | 101 | 36.92% |
| 2009 | 74.0 | 164.13% |
| 2008 | 28.0 | 210.09% |
| 2007 | 9.03 | 75.44% |
| 2006 | 5.15 | -32.86% |
| 2005 | 7.67 | -80.38% |
| 2004 | 39.1 | 15.37% |
| 2003 | 33.9 | -40.03% |
| 2002 | 56.5 | -83.96% |
| 2001 | 352 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | N/A | N/A | 🇺🇸 USA |